About ViramuneViramune is a non-nucleoside reverse transcriptase inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV – 1 infection. This indication is based on a principle clinical trial that demonstrated prolonged suppression of HIV-RNA and two smaller supportive studies. GSK is a leader in HIV / AIDS treatment for patient, and offers its antiretroviral to 63 of least developed countries and sub-Saharan Africa at not-for – profit prices. Related links: HIV / AIDS Website Boehringer Ingelheim Global website of GlaxoSmithKline.
Contact: Boehringer Ingelheim GmbH Corporate Division Communications Julia Meyer – Kleinmann 55216 Ingelheim am Rhein GERMANY Phone:+49/6132/77 82 71 Fax:+49 / 6132 / 77 66 01 E-mailReferences: 1 Guidance for Industry fixed Dose Combination and Co – Packaged Drug Products for the treatment of HIV.They found out that this strategy should raised survival, prevent costly opportunistic infections, turns early transmission and is very inexpensive.. In Washington, DC of early treating HIV Add Expanded Analysis Of HPTN 052 findings of the study shown, where the HIV Prevention Trials Network 052 investigators published their seminal study indicates Results The last year that the treatment the transmitting HIV so as to reduce 96 percent of serodiscordant pairs of, were matters on the cost of the early antiretroviral therapy is raised and if it were to be implemented worldwide. Today at the XIX International AIDS Conference in Washington, DC show that the treatment of as prevent very cost effective being.